ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00363753
Recruitment Status : Withdrawn
First Posted : August 15, 2006
Last Update Posted : April 2, 2007
Sponsor:
Information provided by:
University of California, San Diego

August 10, 2006
August 15, 2006
April 2, 2007
August 2006
Not Provided
mRS at three months.
Same as current
Complete list of historical versions of study NCT00363753 on ClinicalTrials.gov Archive Site
Incidence of stroke at three months, bleeding events.
Same as current
Not Provided
Not Provided
 
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.
Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Transient Ischemic Attack
  • Stroke
  • Aspirin
  • Clopidogrel
Drug: aspirin versus clopidogrel
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
20
Same as current
March 2007
Not Provided

Inclusion Criteria:

  • Age 18 and older.
  • Stroke or transient ischemic attack (TIA) while taking aspirin within one week of consent.
  • Women of child-bearing potential will be included only if there is a negative pregnancy test and they agree to birth control during the treatment period.

Exclusion Criteria:

  • Any medical indication for a specific antiplatelet agent (aspirin, clopidogrel, ticlopidine, aggrenox), or an indication for a combination of antiplatelet agents.
  • Any medical indication for anticoagulation, except subcutaneous heparin for deep vein thrombosis prophylaxis.
  • Allergy to aspirin or clopidogrel.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00363753
UCSD IRB #060452
Not Provided
Not Provided
Not Provided
Not Provided
University of California, San Diego
Not Provided
Principal Investigator: Matt B Jensen, MD UCSD Stroke Center
University of California, San Diego
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP